Hilltop Partners’s AbbVie ABBV Stock Holding History

Hilltop Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$802K	Buy	3,688 +66	+2%	+$14.6K	0.21%	58
2025 Q4	$828K	Buy	3,622 +35	+1%	+$7.97K	0.21%	56
2025 Q3	$831K	Buy	3,587 +6	+0.2%	+$1.22K	0.25%	55
2025 Q2	$665K	Sell	3,581 -215	-6%	-$40K	0.2%	62
2025 Q1	$795K	Sell	3,796 -24	-0.6%	-$4.67K	0.27%	53
2024 Q4	$679K	Sell	3,820 -43	-1%	-$7.91K	0.23%	60
2024 Q3	$763K	Buy	3,863 +4	+0.1%	+$747	0.26%	59
2024 Q2	$662K	Buy	3,859 +55	+1%	+$9.11K	0.24%	58
2024 Q1	$693K	Buy	3,804 +2	+0.1%	+$345	0.25%	57
2023 Q4	$589K	Buy	3,802 +123	+3%	+$17.9K	0.23%	55
2023 Q3	$548K	Sell	3,679 -15	-0.4%	-$2.2K	0.23%	57
2023 Q2	$498K	Buy	3,694 +615	+20%	+$90.2K	0.21%	61
2023 Q1	$491K	Buy	3,079 +6	+0.2%	+$917	0.22%	41
2022 Q4	$497K	Buy	+3,073	New	+$471K	0.27%	30

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hilltop Partners's ABBV Position: Q1 2026 in Review

Hilltop Partners increased its AbbVie (ABBV) stake by 1.8% in Q1 2026, buying an estimated $14.6K and bringing the position to 3,688 shares worth $802K. The position accounts for 0.21% of the portfolio, ranked #58.

Hilltop Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $831K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hilltop Partners held 3,688 shares of AbbVie worth $802K as of Q1 2026.
Hilltop Partners bought 66 AbbVie shares in Q1 2026, an estimated $14.6K.
AbbVie made up 0.21% of Hilltop Partners's portfolio in Q1 2026, its #58 holding.
Hilltop Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Hilltop Partners's AbbVie position peaked at $831K in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hilltop Partners's 13F filing for Q1 2026, filed 12 May 2026.